Neos Therapeutics (NASDAQ: NEOS) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Neos Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neos Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neos Therapeutics 0 0 4 0 3.00
Neos Therapeutics Competitors 940 3772 5984 164 2.49

Neos Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 82.07%. As a group, “Pharmaceuticals” companies have a potential upside of 25.96%. Given Neos Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Neos Therapeutics is more favorable than its competitors.

Valuation & Earnings

This table compares Neos Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Neos Therapeutics $15.62 million -$69.70 million -2.07
Neos Therapeutics Competitors $7.86 billion $2.50 billion 0.98

Neos Therapeutics’ competitors have higher revenue and earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Neos Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neos Therapeutics -511.74% -611.78% -80.97%
Neos Therapeutics Competitors -3,613.10% -47.65% -8.15%

Institutional and Insider Ownership

44.3% of Neos Therapeutics shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 5.2% of Neos Therapeutics shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Neos Therapeutics has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Neos Therapeutics’ competitors have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.


Neos Therapeutics competitors beat Neos Therapeutics on 7 of the 12 factors compared.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with's FREE daily email newsletter.